Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Zhao, Wenyuan; Wang, Jun; Luo, Qingxi; Peng, Wei; Li, Bin; Wang, Lei; Zhang, Chunfang; Duan, Chaojun

doi:10.1186/s12920-020-00834-6

Cited by 5 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LINC01137 has been shown to play an oncogenic role in NSCLC and oral squamous cell carcinoma, which is similar with our results that NSCLC patients with low expression of LINC01137 were likely to exhibit better outcomes (32,33). Zhao et al demonstrated that LINC02310, as an enhancer in LUAD, obviously promoted the growth and proliferation of LUAD cells, and its overexpression caused low survival probability (34). In addition, AC017100.1 was shown to be a protective factor for the prognosis of prostate cancer (35).…”

Section: Discussionsupporting

confidence: 91%

“…These TNF-related lncRNAs were involved in carcinogenesis, and inflammatory and immune responses (22)(23)(24)(25). A number of studies have also demonstrated that some of TNF-related lncRNAs are closely associated with cancer proliferation and survival (32)(33)(34)(35)(36)(37)(38). Thus, we analyzed the expression patterns and clinical significance of TNFrelated lncRNAs in LUAD.…”

Section: Discussionmentioning

confidence: 99%

“…Zhao et al . demonstrated that LINC02310, as an enhancer in LUAD, obviously promoted the growth and proliferation of LUAD cells, and its overexpression caused low survival probability ( 34 ). In addition, AC017100.1 was shown to be a protective factor for the prognosis of prostate cancer ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) has become one of the most lethal cancers, for which the recurrence and survival rates remain unfavorable. The tumor necrosis factor (TNF) family is involved in tumorigenesis and tumor progression. Various long non-coding RNAs (lncRNAs) play important roles by mediating the TNF family in cancer. Therefore, this study aimed to construct a TNF-related lncRNA signature to predict prognosis and immunotherapy response in LUAD. Methods:The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.Results: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high-and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy. Conclusions:For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Two ARlncRNAs in the signature have been reported in the relevant literature. Zhao et al demonstrated that LINC02310 significantly promoted the growth and proliferation of LUAD [ 24 ]. Experiments showed that HAS2-AS1 overexpression strongly reduced breast cancer cell viability, migration and invasion [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma

Wu,

Zhang,

Feng

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Methods for predicting the outcome of lung adenocarcinoma (LUAD) in the clinic are limited. Anoikis is an important route to programmed cell death in LUAD, and the prognostic value of a model constructed with anoikis-related lncRNAs (ARlncRNAs) in LUAD is unclear. Methods: Transcriptome and basic information for LUAD patients was obtained from the Cancer Genome Atlas. Coexpression and Cox regression analyses were utilized to identify prognostically significant ARlncRNAs and construct a prognostic signature. Furthermore, the signature was combined with clinical characteristics to create a nomogram. Finally, we performed principal component, enrichment, tumor mutation burden (TMB), tumor microenvironment (TME) and drug sensitivity analyses to evaluate the basic research and clinical merit of the signature. Results: The prognostic signature developed with eleven ARlncRNAs can accurately predict that high-risk group patients have a worse prognosis, as proven by the receiver operating characteristic (ROC) curve (AUC: 0.718). Independent prognostic analyses indicated that the risk score is a significant independent prognostic element for LUAD (P<0.001). In the high-risk group, enrichment analysis demonstrated that glucose metabolism and DNA replication were the main enrichment pathways. TMB analysis indicated that the high-risk group had a high TMB (P<0.05). Drug sensitivity analyses can recognize drugs that are sensitive to different risk groups. Finally, 11 ARlncRNAs of this signature were verified by RT-qPCR analysis. Conclusions: A novel prognostic signature developed with 11 ARlncRNAs can accurately predict the OS of LUAD patients and offer clinical guidance value for immunotherapy and chemotherapy treatment.

show abstract

“…LINC02310 has hardly been reported. Only a few scholars found that its overexpression would lead to poor prognosis in lung adenocarcinoma patients [27], CCK-8 assay and colony formation assay also showed that it could act as an enhancer in lung adenocarcinoma [28], and downregulation of LINC02310 could prevent proliferation, migration, invasion, and the epithelial-mesenchymal transition of non-small cell lung cancer cells, promote apoptosis, and enhance radiosensitivity. However, the role of these non-coding RNAs in the prognosis of gastric cancer is not yet clear and needs to be further mapped in the future.…”

Section: Discussionmentioning

confidence: 99%

Exploring the Prognosis-Related Genetic Variation in Gastric Cancer Based on mGWAS

Zhang,

Lyu,

Chen

et al. 2023

IJMS

View full text Add to dashboard Cite

The use of metabolome genome-wide association studies (mGWAS) has been shown to be effective in identifying functional genes in complex diseases. While mGWAS has been applied to biomedical and pharmaceutical studies, its potential in predicting gastric cancer prognosis has yet to be explored. This study aims to address this gap and provide insights into the genetic basis of GC survival, as well as identify vital regulatory pathways in GC cell progression. Genome-wide association analysis of plasma metabolites related to gastric cancer prognosis was performed based on the Generalized Linear Model (GLM). We used a log-rank test, LASSO regression, multivariate Cox regression, GO enrichment analysis, and the Cytoscape software to visualize the complex regulatory network of genes and metabolites and explored in-depth genetic variation in gastric cancer prognosis based on mGWAS. We found 32 genetic variation loci significantly associated with GC survival-related metabolites, corresponding to seven genes, VENTX, PCDH 7, JAKMIP1, MIR202HG, MIR378D1, LINC02472, and LINC02310. Furthermore, this study identified 722 Single nucleotide polymorphism (SNP) sites, suggesting an association with GC prognosis-related metabolites, corresponding to 206 genes. These 206 possible functional genes for gastric cancer prognosis were mainly involved in cellular signaling molecules related to cellular components, which are mainly involved in the growth and development of the body and neurological regulatory functions related to the body. The expression of 23 of these genes was shown to be associated with survival outcome in gastric cancer patients in The Cancer Genome Atlas (TCGA) database. Based on the genome-wide association analysis of prognosis-related metabolites in gastric cancer, we suggest that gastric cancer survival-related genes may influence the proliferation and infiltration of gastric cancer cells, which provides a new idea to resolve the complex regulatory network of gastric cancer prognosis.

show abstract

Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Cited by 5 publications

References 53 publications

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma

Exploring the Prognosis-Related Genetic Variation in Gastric Cancer Based on mGWAS

Contact Info

Product

Resources

About